CIITA rabbit pAb
ENT-A6117
Description
| REF | ENT-A6117 |
|---|---|
| Category | Antibody Polyclonal |
| Description | CIITA rabbit pAb |
| Source | Rabbit |
| Applications | WB;ELISA |
| Reactivity | Human;Mouse;Rat |
| Reactivity | Human;Mouse;Rat |
| Dilution | Western Blot: 1/500 – 1/2000. ELISA: 1/10000. Not yet tested in other applications. |
| Immunogen | The antiserum was produced against synthesized peptide derived from human CIITA. AA range:706-755 |
| Storage Stability | -20°C/1 year |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1 mg/ml |
| Observed Band KD | 123kD |
| Human Gene ID | 4261 |
| Human Swiss Prot Nº | P33076 |
| Subcellular Location | Nucleus . Nucleus, PML body . Recruited to PML body by PML. |
Other Name: CIITA; MHC2TA; MHC class II transactivator; CIITA
Background: class II major histocompatibility complex transactivator(CIITA) Homo sapiens This gene encodes a protein with an acidic transcriptional activation domain, 4 LRRs (leucine-rich repeats) and a GTP binding domain. The protein is located in the nucleus and acts as a positive regulator of class II major histocompatibility complex gene transcription, and is referred to as the “master control factor” for the expression of these genes. The protein also binds GTP and uses GTP binding to facilitate its own transport into the nucleus. Once in the nucleus it does not bind DNA but rather uses an intrinsic acetyltransferase (AT) activity to act in a coactivator-like fashion. Mutations in this gene have been associated with bare lymphocyte syndrome type II (also known as hereditary MHC class II deficiency or HLA class II-deficient combined immunodeficiency), increased susceptibility to rheumatoid arthritis, multiple sclerosis, and possibly myocardi
